The primary objective of this study was to evaluate a novel flow cytometry-based assay of quantifying platelet phosphorylation of vasodilator-stimulated phosphoprotein (P-VASP) in cats that received clopidogrel treatment. Eight healthy cats received 18.75 mg PO q24h of clopidogrel for 7 days. Prior to and after clopidogrel treatment, blood was collected for ADP-induced light transmission aggregometry (LTA) and P-VASP measurement by flow cytometry. Flow cytometry measurement of P-VASP levels was used to derive platelet reactivity index (PRI) before and after clopidogrel treatment. Based on P-VASP and LTA findings, platelet response to ADP was significantly attenuated after 7 days of clopidogrel treatment. By eliciting the competing platelet pathways of P2Y12 and cAMP using ADP and PGE1, respectively, ADP had no effect on P-VASP levels following clopidogrel treatment (p = 0.94). Clopidogrel also significantly decreased PRI from 28.84 ± 28.52% to 1.69 ± 12.39% (p = 0.0078). PRI on day 8 correlated moderately with the degree of slope inhibition on LTA (r = -0.4, p = 0.4). Flow cytometry analysis of P-VASP is effective at monitoring the inhibitory effects of clopidogrel on feline platelets.

中文翻译：

---

氯吡格雷对猫血小板中P2Y12抑制作用的评估使用流式细胞术定量血管扩张剂刺激的磷酸蛋白磷酸化。

这项研究的主要目的是评估一种新颖的基于流式细胞术的定量检测接受氯吡格雷治疗的猫中血管扩张剂刺激的磷蛋白（P-VASP）血小板磷酸化的分析方法。八只健康的猫每24小时服用氯吡格雷18.75 mg PO，持续7天。在氯吡格雷治疗之前和之后，收集血液用于ADP诱导的光凝集法（LTA）和通过流式细胞术测量P-VASP。P-VASP水平的流式细胞仪测量用于得出氯吡格雷治疗前后的血小板反应性指数（PRI）。根据P-VASP和LTA的发现，氯吡格雷治疗7天后，血小板对ADP的反应明显减弱。通过分别使用ADP和PGE1引发P2Y12和cAMP的竞争性血小板通路，氯吡格雷治疗后ADP对P-VASP水平无影响（p = 0.94）。氯吡格雷的PRI也从28.84±28.52％显着降低至1.69±12.39％（p = 0.0078）。第8天的PRI与LTA的斜率抑制程度呈中等相关性（r = -0.4，p = 0.4）。P-VASP的流式细胞术分析可有效监测氯吡格雷对猫血小板的抑制作用。